Evidence mapPaperPMID 37558746Full record

ArticleScientific reports2023

Alpha cell receptor for advanced glycation end products associate with glucagon expression in type 1 diabetes.

Sherman S Leung, Nataliya Lenchik, Clayton Mathews, Alberto Pugliese, Domenica A McCarthy, Selena Le Bagge, Adam Ewing, Mark Harris, Kristen J Radford, Danielle J Borg and 2 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 2 countries.

Sherman S LeungGlycation and Diabetes Complications, Mater Research Institute, Translational Research Institute (TRI), The University of Queensland (MRI-UQ), 37 Kent Street, Woolloongabba, Brisbane, QLD, 4102, Australia.
Nataliya LenchikDivision of Endocrinology, Department of Medicine, University of Tennessee Health Science Center, Memphis, TN, USA.
Clayton MathewsDivision of Endocrinology, Department of Medicine, University of Tennessee Health Science Center, Memphis, TN, USA.
Alberto PuglieseDivision of Endocrinology, Department of Microbiology and Immunology, Department of Medicine, Diabetes Research Institute, Miller School of Medicine, University of Miami, Miami, FL, USA.
Domenica A McCarthyGlycation and Diabetes Complications, Mater Research Institute, Translational Research Institute (TRI), The University of Queensland (MRI-UQ), 37 Kent Street, Woolloongabba, Brisbane, QLD, 4102, Australia.
Selena Le BaggeGlycation and Diabetes Complications, Mater Research Institute, Translational Research Institute (TRI), The University of Queensland (MRI-UQ), 37 Kent Street, Woolloongabba, Brisbane, QLD, 4102, Australia.
Adam EwingFaculty of Medicine, The University of Queensland, Brisbane, Australia.
Mark HarrisFaculty of Medicine, The University of Queensland, Brisbane, Australia.
Kristen J RadfordFaculty of Medicine, The University of Queensland, Brisbane, Australia.
Danielle J BorgGlycation and Diabetes Complications, Mater Research Institute, Translational Research Institute (TRI), The University of Queensland (MRI-UQ), 37 Kent Street, Woolloongabba, Brisbane, QLD, 4102, Australia.
Ivan Gerling *Division of Endocrinology, Department of Medicine, University of Tennessee Health Science Center, Memphis, TN, USA.
Josephine M Forbes *Glycation and Diabetes Complications, Mater Research Institute, Translational Research Institute (TRI), The University of Queensland (MRI-UQ), 37 Kent Street, Woolloongabba, Brisbane, QLD, 4102, Australia. josephine.forbes@mater.uq.edu.au.ORCID http://orcid.org/0000-0002-5595-8174
Translational Research Institute · AUUniversity of Tennessee Health Science Center · USGriffith University · AUMater Health Services · AUUniversity of Miami · US

Funding

NIDDK NIH HHS UC4 DK104155
6 · The paper itself

Abstract

Hypoglycemia in type 1 diabetes associates with changes in the pancreatic islet α cells, where the receptor for advanced glycation end products (RAGE) is highly expressed. This study compared islet RAGE expression in donors without diabetes, those at risk of, and those with type 1 diabetes. Laser-dissected islets were subject to RNA bioinformatics and adjacent pancreatic tissue were assessed by confocal microscopy. We found that islets from type 1 diabetes donors had differential expression of the RAGE gene (AGER) and its correlated genes, based on glucagon expression. Random forest machine learning revealed that AGER was the most important predictor for islet glucagon levels. Conversely, a generalized linear model identified that glucagon expression could be predicted by expression of RAGE signaling molecules, its ligands and enzymes that create or clear RAGE ligands. Confocal imaging co-localized RAGE, its ligands and signaling molecules to the α cells. Half of the type 1 diabetes cohort comprised of adolescents and a patient with history of hypoglycemia-all showed an inverse relationship between glucagon and RAGE. These data confirm an association between glucagon and islet RAGE, its ligands and signaling pathways in type 1 diabetes, which warrants functional investigation into a role for RAGE in hypoglycemia.

Indexed as

Diabetes Mellitus, Type 1Glucagon-Secreting CellsHypoglycemiaReceptor for Advanced Glycation End ProductsAdolescentGlucagonGlycation End Products, AdvancedHumansLigandsAGER protein, humanGlucagonGlycation End Products, AdvancedLigandsReceptor for Advanced Glycation End Products

Identifiers

PMID37558746
PMCPMC10412557
OpenAlexW4385690460

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.